vs
Side-by-side financial comparison of DHT Holdings, Inc. (DHT) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $107.3M, roughly 1.2× DHT Holdings, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -24.5%).
DHT Holdings, Inc. is an independent international crude oil tanker operator that owns and manages a fleet of very large crude carriers. It offers marine transportation services for crude oil across major global trade routes, serving clients including leading oil producers, refineries, and commodity trading enterprises worldwide.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
DHT vs TVTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.3M | $129.7M |
| Net Profit | $44.8M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 44.2% | -25.0% |
| Net Margin | 41.7% | — |
| Revenue YoY | -24.5% | 73.4% |
| Net Profit YoY | 27.3% | — |
| EPS (diluted) | $0.28 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $129.7M | ||
| Q3 25 | $107.3M | $164.9M | ||
| Q2 25 | — | $114.4M | ||
| Q1 25 | — | $81.7M | ||
| Q4 24 | — | $74.8M | ||
| Q3 24 | $142.1M | $62.9M | ||
| Q2 24 | — | $54.1M | ||
| Q1 24 | — | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $44.8M | $25.7M | ||
| Q2 25 | — | $-12.8M | ||
| Q1 25 | — | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $35.2M | $-54.8M | ||
| Q2 24 | — | $-70.4M | ||
| Q1 24 | — | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | 44.2% | 15.1% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | — | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | 29.7% | -89.3% | ||
| Q2 24 | — | -125.1% | ||
| Q1 24 | — | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | 41.7% | 15.6% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | — | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.8% | -87.1% | ||
| Q2 24 | — | -130.1% | ||
| Q1 24 | — | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $0.28 | $0.28 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $0.22 | $-0.70 | ||
| Q2 24 | — | $-0.91 | ||
| Q1 24 | — | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $81.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $114.8M |
| Total Assets | $1.4B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | $81.3M | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | $73.8M | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | — | $114.8M | ||
| Q3 25 | $1.1B | $73.6M | ||
| Q2 25 | — | $32.7M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $1.0B | $-30.5M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | — | $605.2M | ||
| Q3 25 | $1.4B | $538.6M | ||
| Q2 25 | — | $555.3M | ||
| Q1 25 | — | $548.8M | ||
| Q4 24 | — | $594.1M | ||
| Q3 24 | $1.5B | $504.4M | ||
| Q2 24 | — | $551.1M | ||
| Q1 24 | — | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.7M | ||
| Q3 25 | $60.9M | $14.3M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | — | $-42.2M | ||
| Q4 24 | — | $-35.7M | ||
| Q3 24 | $80.1M | $-42.5M | ||
| Q2 24 | — | $-40.2M | ||
| Q1 24 | — | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.28× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DHT
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
